CESCA Therapeutics to Present at the 2017 International Symposium of Translational Medicine in Stem Cell … – Yahoo Finance
By LizaAVILA
RANCHO CORDOVA, Calif., April 11, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Dr. Xiaochun (Chris) Xu, Chairman and Interim Chief Executive Officer and Chairman of Boyalife Group, will present an overview of the Companys cardiovascular clinical research program at the 2017 International Symposium of Translational Medicine in Stem Cell Myocardial Repair, being held April 10-12, 2017 at the Hope Hotel in Shanghai, China.
Details of the presentation are as follows:
Despite recent therapeutic and surgical advances, the effects of peripheral arterial disease, including heart attack and critical limb ischemia (CLI), remain among the worlds leading causes of morbidity and mortality and represent a rapidly escalating public health crisis, noted Dr. Xu. I look forward to presenting a review of our latest findings, including key feasibility study results and an overview of our Phase 3 Critical Limb Ischemia Rapid Stemcell Treatment (CLIRST) trial, which we believe highlight the potential of Cesca Therapeutics proprietary AutoXpress point-of-care platform to deliver autologous cell-based therapies that may represent a new paradigm in patient treatment going forward.
About the Symposium of Translational Medicine in Stem Cell Myocardial Repair
The 2017 International Symposium of Translational Medicine in Stem Cell Myocardial Repair brings together more than 650 of the worlds cardiac disease thought leaders to discuss the potential of translational and regenerative medicine in treating myocardial infarction (MI) and cardiac failure. The symposium is co-sponsored by the Shanghai Society for Cell Biology, the Institute of Health Sciences, the Shanghai Cardiovascular Disease Institute, the Guangzhou Institutes of Biomedicine and Health, and the Key Laboratory of Stem Cell Biology, Shanghai.
About Cesca Therapeutics Inc.
Cesca is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. Cesca is an affiliate of the Boyalife Group (http://www.boyalifegroup.com), a China-based industrial-research alliance among top research institutes for stem cell and regenerative medicine.
Forward-Looking Statement
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on managements current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
- UMass Amherst Engineers Create Bioelectronic Mesh Capable of Growing with Cardiac Tissues for Comprehensive ... - Diagnostic and Interventional... - March 26th, 2024
- Stressing heart cells to study disease - AIP.ORG - American Institute of Physics - March 18th, 2024
- 'Heart-on-a-chip' to test chemotherapies and other cancer drugs for heart toxicity - Medical Xpress - February 7th, 2024
- Treating and preventing abnormal heart beats with stem cell muscle grafts - Medical Xpress - February 7th, 2024
- Stem Cell Therapy Boosts Quality of Life for People With Advanced Heart Failure - MedicineNet - December 20th, 2023
- Regenerative medicine can be a boon for those with Drug-Resistant Tuberculosis - Hindustan Times - April 21st, 2023
- Cardiac stem cells: Current knowledge and future prospects - April 13th, 2023
- Stem cell therapies in cardiac diseases: Current status and future ... - April 13th, 2023
- Stem Cell and Regenerative Biology | Johns Hopkins Heart and Vascular ... - April 13th, 2023
- Center for Regenerative Biotherapeutics - Cardiac Regeneration - April 13th, 2023
- MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com - March 25th, 2023
- CAREDX, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com - March 1st, 2023
- A Possible Connection between Mild Allergic Airway Responses and Cardiovascular Risk Featured in Toxicological Sciences - Newswise - February 4th, 2023
- Baby's life saved by surgeon who carried out world's first surgery ... - December 25th, 2022
- An organoid model of colorectal circulating tumor cells with stem cell ... - December 25th, 2022
- Skeletal Muscle Cell Induction from Pluripotent Stem Cells - December 1st, 2022
- Stem-cell niche - Wikipedia - December 1st, 2022
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 13th, 2022
- Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $0 Thousand by 2027 - Yahoo Finance - October 13th, 2022
- Scientists Spliced Human Brain Tissue Into The Brains of Baby Rats - ScienceAlert - October 13th, 2022
- Decoding the transcriptome of calcified atherosclerotic plaque at single-cell resolution | Communications Biology - Nature.com - October 13th, 2022
- Global Synthetic Stem Cells Market Is Expected To Reach Around USD 42 Million By 2025 - openPR - October 13th, 2022
- Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine -... - October 13th, 2022
- Regenerative Medicine For Heart Diseases: How It Is Better Than Conventional Treatments | TheHealthSite.co - TheHealthSite - October 5th, 2022
- 'Love hormone' oxytocin could help reverse damage from heart attacks via cell regeneration - Study Finds - October 5th, 2022
- Recapitulating Inflammation: How to Use the Colon Intestine-Chip to Study Complex Mechanisms of IBD - Pharmaceutical Executive - September 27th, 2022
- Adult Stem Cells // Center for Stem Cells and Regenerative Medicine ... - September 19th, 2022
- CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease - Cardiovascular Diabetology - Cardiovascular... - September 19th, 2022
- Kite's CAR T-cell Therapy Yescarta First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and... - September 19th, 2022
- Neural crest - Wikipedia - September 3rd, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - September 3rd, 2022
- Discover the Mental and Physical Health Benefits of Fasting - Intelligent Living - September 3rd, 2022
- Heart Association fellowship to support research - Binghamton - August 26th, 2022
- Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration | Communications Biology -... - August 26th, 2022
- High intensity interval training protects the heart against acute myocardial infarction through SDF-1a, CXCR4 receptors and c-kit levels - Newswise - August 26th, 2022
- Yale University: Uncovering New Approaches to a Common Inherited Heart Disorder | India Education - India Education Diary - August 10th, 2022
- Heart failure in obesity: insights from proteomics in patients treated with or without weight-loss surgery | International Journal of Obesity -... - August 10th, 2022
- Pigs died after heart attacks. Scientists brought their cells back to life. - Popular Science - August 10th, 2022
- Protocol for a Nested, Retrospective Study of the Australian Placental Transfusion Study Cohort - Cureus - August 10th, 2022
- Autologous Cell Therapy Market Size to Grow by USD 4.11 billion, Bayer AG and Brainstorm Cell Therapeutics Inc. Among Key Vendors - Technavio - PR... - August 2nd, 2022
- UTSW researcher part of team awarded $36 million heart research grant - The Dallas Morning News - August 2nd, 2022
- Buffalo center fuels research that can save your life from heart disease and stroke - Buffalo News - August 2nd, 2022
- Hyperglycaemia-Induced Impairment of the Autorhythmicity and Gap Junction Activity of Mouse Embryonic Stem Cell-Derived Cardiomyocyte-Like Cells -... - July 25th, 2022
- NASA's Solution to Stem Cell Production is Out of this World - BioSpace - July 25th, 2022
- Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor | Signal Transduction and Targeted Therapy - Nature.com - July 25th, 2022
- 'My Teen Sweetheart And I Drifted Apart. 30 Years Later I Made a Shocking Discovery' - Newsweek - July 25th, 2022
- EU: New Blood? Proposed Revisions to the EUs Blood, Tissues and Cells Rules - GlobalComplianceNews - July 25th, 2022
- Stem Cells Market to Expand at a CAGR of 10.4% from 2021 to 2028 Travel Adventure Cinema - Travel Adventure Cinema - July 25th, 2022
- Cell Separation Technologies Market Expands with Rise in Prevalence of Chronic Diseases, States TMR Study - GlobeNewswire - July 25th, 2022
- Dental Membrane and Bone Graft Substitutes Market to Exceed Value of US$ 1,337 Mn by 2031 - PR Newswire UK - July 25th, 2022
- Stem Cells Used to Repair Heart Defects in Children - NBC 5 Dallas-Fort Worth - July 16th, 2022
- Pneumonia and Heart Disease: What You Should Know - Healthline - July 16th, 2022
- Promising solution to fatal genetic-disorder complications discovered by University professor and Ph.D. candidate - Nevada Today - July 16th, 2022
- Current and advanced therapies for chronic wound infection - The Pharmaceutical Journal - July 16th, 2022
- Why do some women struggle to breastfeed? A UCSC researcher on what we know, and don't - Lookout Santa Cruz - July 16th, 2022
- Mesenchymal stem cells: from roots to boost - PMC - July 8th, 2022
- New study allows researchers to more efficiently form human heart cells from stem cells - University of Wisconsin-Madison - July 8th, 2022
- Dr Victor Chang saved hundreds of lives. 31 years ago today, he was murdered. - Mamamia - July 8th, 2022
- Exosome Therapeutics Market Research Report Size, Share, New Trends and Opportunity, Competitive Analysis and Future Forecast Designer Women -... - July 8th, 2022
- Cell Line Development Market: Increase in Prevalence of Cancer and Other Chronic Diseases to Drive the Market - BioSpace - July 8th, 2022
- Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and... - July 8th, 2022
- What New Advances are there in 3D Bioprinting Tissues? - AZoM - June 30th, 2022
- Technical Advancements & Innovative Products Likely to Expand Application of Surgical Meshes in Untapped Domains, States Fact.MR - BioSpace - June 30th, 2022
- Liso-cel Approval Provides Earlier, Expanded Access to CAR T-cell Therapy in Second-line LBCL - OncLive - June 30th, 2022
- Stem cells, embryos, and the environment: a context for both science ... - June 20th, 2022
- Getting to the heart of engineering a heart - Harvard School of Engineering and Applied Sciences - June 11th, 2022
- 'Ghost heart': Built from the scaffolding of a pig and the patient's cells, this cardiac breakthrough may soon be ready for transplant into humans -... - June 11th, 2022
- Current and Future Innovations in Stem Cell Technologies - Labmate Online - June 11th, 2022
- Bioabsorbable Stents Market to Grow at a Fine CAGR of 9.6% through 2032: Improvements in Healthcare Infrastructure and Growing Geriatric Population to... - June 11th, 2022
- Is a Bioengineered Heart From Recipient Tissues the Answer to the Shortage of Donors in Heart Transplantation? - Cureus - May 29th, 2022
- Global Heart Failure Pipeline Market Research Report 2022: Comprehensive Insights About 90+ Companies and 90+ Pipeline Drugs - ResearchAndMarkets.com... - May 29th, 2022
- Whats a heart attack? How can you tell if youre on the edge of one? - Sydney Morning Herald - May 29th, 2022
- Heart, cancer and diabetes projects among winners of funding boost for stem cell therapies - The Globe and Mail - May 13th, 2022
- Meet the Canadian researcher determined to take the animals out of lab testing - CBC.ca - May 13th, 2022
- Stem cell-based regenerative medicine - PMC - April 29th, 2022
- Global Stem Cell Market To Be Driven By Increasing Activities To Use Stem Cells In Regenerative Medicines In The Forecast Period Of 2022-2027 ... - April 29th, 2022
- Montefiore Einstein Cancer Center Finds CAR-T Therapy Effective in Black and Hispanic Patients - Newswise - April 29th, 2022
- Global, regional, and national burden of hypertensive heart disease during 19902019: an analysis of the global burden of disease study 2019 - BMC... - April 29th, 2022
- First all-private astronaut team aboard space station heads for splashdown - KFGO - April 29th, 2022
- James Woody, CEO of 180 Life Sciences: Developing New Therapies to Treat Inflammatory Diseases - DocWire News - April 29th, 2022